Amgen colorectal cancer drug gains expanded U.S. approval

Amgen (AMGN) says the FDA has approved its Vectibix drug as an initial treatment in patients with a type of advanced colorectal cancer who first undergo genetic screening.

AMGN says the drug was cleared as an initial treatment in conjunction with chemotherapy for patients whose tumors have a gene mutation that renders their cancer susceptible to the medicine.

The FDA agency also cleared Qiagen’s (QGEN) test that can show whether Vectibix will be effective in patients.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs